NCT01730846View on ClinicalTrials.gov

Does Doxazosin Attenuate Stress-induced Smoking and Improve Clinical Outcomes?

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
Smoking
Interventions
DRUG

Doxazosin 4mg/day

4 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study. 5-day taper at the end of the study.

DRUG

Placebo

Placebo

DRUG

Doxazosin 8mg/day

8 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study. 5-day taper at the end of the study.

Trial Locations (1)

06519

Yale Center for Clinical Investigations, Yale University, New Haven

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Yale University

OTHER

NCT01730846 - Does Doxazosin Attenuate Stress-induced Smoking and Improve Clinical Outcomes? | Biotech Hunter | Biotech Hunter